• 1
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347(6): 41729.
  • 2
    Wilson J, Hair C, Knight R et al. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis 2010; 16: 15506.
  • 3
    Thia KT, Loftus EV Jr, Sandborn WJ et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 316782.
    Direct Link:
  • 4
    Moum B, Ekbom A, Vatn M et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut 1997; 40: 32832.
  • 5
    Pera A, Bellando P, Caldera D et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology 1987; 92: 1815.
  • 6
    Tremaine WJ. Is indeterminate colitis determinable? Curr Gastroenterol Rep 2012; 14: 1625.
  • 7
    Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol 2007; 22: 16717.
  • 8
    Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14: 25449.
  • 9
    Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004; 16: 116771.
  • 10
    Mokrowiecka A, Daniel P, Slomka M et al. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology 2009; 56: 1626.
  • 11
    Zholudev A, Zurakowski D, Young W et al. Serologic testing with ANCA, ASCA, and anti-ompC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99: 223541.
    Direct Link:
  • 12
    Lawrance IC, Hall A, Leong R et al. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis 2005; 11: 8907.
  • 13
    Lawrance IC, Murray K, Hall A et al. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 2004; 99: 218694.
    Direct Link:
  • 14
    Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006; 52: 17181.
  • 15
    Bjerrum JT, Nyberg C, Olsen J, Nielsen OH. Assessing the Validity of a Multi-Gene Analysis in the Diagnostics of Inflammatory Bowel Disease, published in this issue.
  • 16
    Von Stein P, Lofberg R, Kuznetsov NV et al. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. Gastroenterology 2008; 134: 186981.
  • 17
    Smulders YM. A two-step manuscript submission process can reduce publication bias. J Clin Epidemiol 2013; 66: 9467.
  • 18
    Wager E, Williams P. “Hardly worth the effort”? Medical journals' policies and their editors' and publishers' views on trial registration and publication bias: quantitative and qualitative study BMJ 2013; 347 doi: 10.1136/bmj.f5248.